🇺🇸 FDA
Patent

US 10087252

Methods and compositions for treating and preventing disease associated with αvβ5 integrin

granted A61KA61K2039/505A61P

Quick answer

US patent 10087252 (Methods and compositions for treating and preventing disease associated with αvβ5 integrin) held by The Regents of the University of California expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61P, A61P29/00, A61P31/00